Clinical Validation of the RENISCHEM L-FABP POC Assay | MicrobiomeTrials← Back to trialsNCT04864847
Clinical Validation of the RENISCHEM L-FABP POC Assay
CompletedOBSERVATIONAL
Trial Details
Start: 2021-10-01Est. Completion: 2026-02-05
Enrollment target: 382 participants Locations- Chandler Regional Medical Center, Chandler, Arizona, United States
- John Muir Health, Concord, California, United States
- Clearwater Cardiovascular Consultants, Clearwater, Florida, United States
- University of Florida at Jacksonville, Jacksonville, Florida, United States
- Sinai Hospital of Baltimore, Baltimore, Maryland, United States
- University of Oklahoma, Oklahoma City, Oklahoma, United States
Other microbiome trials you might be interested in
Minimal Change Disease (MCD)Membranous NephropathyGlomerulosclerosis, Focal Segmental
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an en…
Los Angeles, United StatesEst. completion Dec 31, 2030
Acute Kidney Injury
Nearly one in ten people who are hospitalized in Canada develop a complication with sudden loss of kidney function, call…
Calgary, CanadaEst. completion Sep 2028